Preclinical evaluation of the therapeutic activity of ABBV-221 against glioma using blood brain barrier opening ultrasound

Project: Research project

Project Details


To test the efficacy of ABBV-221, an epidermal growth factor receptor (EGFR) inhibitor, administered intravenously with blood-brain-barrier (BBB) opening in murine models of glioblastoma (GBM) to ascertain if this delivery strategy prolongs survival.
Effective start/end date3/25/223/24/23


  • AbbVie Inc. (Heimberger AGMT 4/8/22)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.